Neoplasm Treatment Market Analysis

  • Report ID: 3898
  • Published Date: Jul 26, 2024
  • Report Format: PDF, PPT

Neoplasm Treatment Market Analysis

Type (Malignant, Benign)

The global neoplasm treatment market is segmented and analyzed for demand and supply by type into benign, and malignant, out of which, the malignant segment is anticipated to hold the notable share in the global neoplasm treatment market over the forecast period on account of the growing prevalence of malignant, i.e., cancerous neoplasm across the globe. In addition, malignant is a severe kind of neoplasm that usually grow faster than benign and can spread to the whole body of the patient, they are not controlled at the right time, and can invade the nearby tissues. Moreover, the higher exposure to carcinogens, backed by poor lifestyle habits in present times, is estimated to fuel the segment.  According to the World Health Organization, cancer accounted for nearly one in six deaths across the globe in the year 2020.

End-user (Specialty Clinics, Hospital, Cancer Research Center) 

The global neoplasm treatment market is also segmented and analyzed for demand and supply by end-user into specialty clinics, hospital, cancer research center, and others. Out of these, the hospitals segment is projected to hold the largest share over the forecast period in the global neoplasm treatment market. The growth of the segment can be owing to the increasing number of hospitals around the world for the treatment of diseases. Furthermore, the government invests in hospitals for providing treatment facilities to patients belonging to the lower income category. In addition, they are able to deal with the emergency cases with the advanced technologies, and it is expected to increase the segment’s growth in the market.  As per the data reported in 2020, the total number of hospitals in Japan accounted to more than 8,000. In addition, the number of hospitals in Korea has increased to more than 4,000 in the year 2020.

Our in-depth analysis of the global market includes the following segments:

         By Type

  • Malignant
  • Benign

        By End-User

  • Specialty Clinics
  • Hospital
  • Cancer Research Center
  • Others
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 3898
  • Published Date: Jul 26, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of neoplasm treatment is evaluated at USD 204.89 Billion.

The neoplasm treatment market size was valued at USD 187.51 Billion in 2023 and is likely to exceed USD 670.67 Billion by the end of 2036, expanding at over 10.3% CAGR during the forecast period i.e., between 2024-2036. Surging change in genetic mutations, increasing geriatric population are the major factors driving the market growth.

North America is expected to dominate majority industry share by 2036, attributed to rising cases of cancer in the region.

Thermo Fisher Scientific Inc., Bayer AG, Merck & Co., Inc., Novartis AG, Abbott Laboratories, Exelixis, Inc., Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche, Amgen Inc.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying